INVA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
INVA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Innoviva's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2024 was $-33.5 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was $175.0 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Innoviva's annualized ROC % for the quarter that ended in Jun. 2024 was 18.90%. Innoviva's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -119.01%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield. Innoviva's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 11.93%.
The historical data trend for Innoviva's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innoviva Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EBIT | Get a 7-Day Free Trial | 251.56 | 372.58 | 464.35 | 302.74 | 213.26 |
Innoviva Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
EBIT | Get a 7-Day Free Trial | 10.19 | 90.35 | 67.15 | 50.98 | -33.48 |
For the Biotechnology subindustry, Innoviva's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Innoviva's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Innoviva's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $175.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innoviva (NAS:INVA) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Innoviva's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:
ROC % (Q: Jun. 2024 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Mar. 2024 ) | + | Invested Capital (Q: Jun. 2024 )) | / count ) |
= | 218.744 * ( 1 - 11.7% ) | / | ( (1061.631 | + | 982.677) | / 2 ) |
= | 193.150952 | / | 1022.154 | |||
= | 18.90 % |
where
Invested Capital | (Q: Mar. 2024 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 1267.612 | - | 27.624 | - | ( 178.357 | - | max(0, 29.879 | - | 311.342 | + | 178.357 | )) |
= | 1061.631 |
Invested Capital | (Q: Jun. 2024 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 1224.917 | - | 25.237 | - | ( 217.003 | - | max(0, 28.206 | - | 358.277 | + | 217.003 | )) |
= | 982.677 |
Note: The Operating Income data used here is four times the quarterly (Jun. 2024) data.
2. Joel Greenblatt's definition of Return on Capital:
Innoviva's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:
ROC (Joel Greenblatt) % | (Q: Jun. 2024 ) | ||||||
= | EBIT | / | Average of (Net fixed Assets | + | Net Working Capital) | ||
= | EBIT | / | Average of (Property, Plant and Equipment | + | Net Working Capital) | ||
Q: Mar. 2024 | Q: Jun. 2024 | ||||||
= | EBIT | / | ( ( (Property, Plant and Equipment + Net Working Capital) | + | (Property, Plant and Equipment + Net Working Capital) ) | / | count ) |
= | -133.908 | / | ( ( (2.593 + max(104.374, 0)) | + | (3.545 + max(114.519, 0)) ) | / | 2 ) |
= | -133.908 | / | ( ( 106.967 | + | 118.064 ) | / | 2 ) |
= | -133.908 | / | 112.5155 | ||||
= | -119.01 % |
where Working Capital is:
Working Capital | (Q: Mar. 2024 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (76.01 | + | 37.437 | + | 19.538) | - | (27.624 | + | 0.987 | + | 3.5527136788005E-15) |
= | 104.374 |
Working Capital | (Q: Jun. 2024 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (93.98 | + | 36.664 | + | 10.63) | - | (25.237 | + | 1.518 | + | 0) |
= | 114.519 |
When net working capital is negative, 0 is used.
Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.
3. It is also linked to Joel Greenblatt's definition of Earnings Yield:
Innoviva's Earnings Yield (Joel Greenblatt) % for today is calculated as:
Earnings Yield (Joel Greenblatt) % | = | EBIT (TTM) | / | Enterprise Value (Q: Jun. 2024 ) |
= | 174.999 | / | 1466.820 | |
= | 11.93 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Innoviva's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Marianne Zhen | officer: Chief Accounting Officer | C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005 |
Stephen Basso | officer: Chief Financial Officer | C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210 |
Margaret Koziel | officer: Chief Medical Officer | C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Alexander J Denner | 10 percent owner | C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Deborah Birx | director | 3300 LOWELL STREET NW, WASHINGTON DC 20008 |
Sarissa Capital Management Lp | 10 percent owner | 660 STEAMBOAT ROAD, GREENWICH CT 06830 |
Pavel Raifeld | officer: Chief Executive Officer | 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010 |
Sapna Srivastava | director | C/O MYOS CORPORATION, 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927 |
Larry G. Edwards | officer: CEO of La Jolla Pharmaceutical | C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472 |
Plc Glaxosmithkline | 10 percent owner | 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS |
Mark Dipaolo | director | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Kostas D Odysseas | director | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Sarah J. Schlesinger | director | C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Jules Haimovitz | director | 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004 |
George Bickerstaff | director | C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511 |
From GuruFocus
By Value_Insider Value_Insider • 10-19-2022
By Business Wire • 07-31-2024
By GuruFocus Research • 02-14-2024
By Business Wire • 08-25-2023
By Business Wire Business Wire • 04-17-2023
By Business Wire Business Wire • 04-28-2023
By GuruFocus Research • 03-04-2024
By GuruFocus Research • 11-18-2023
By Business Wire • 06-03-2024
By Business Wire Business Wire • 06-06-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.